SEC Filing Summary
Entity and period: The supplied filing is OvaScience, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016—not a filing identified as Tempest Therapeutics, Inc. Investors should verify the issuer before relying on this summary.
Business context
OvaScience was developing fertility treatments based on its EggPC cell technology. Its AUGMENT treatment had been introduced at select international IVF clinics; OvaPrime was in an international clinical study, and OvaTure remained in development. The company reported limited treatment revenue and continuing operating losses.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 or prior period |
|---|---|---|
| Revenue | $0.146 million | $0.015 million |
| Costs of revenue | $1.176 million | $0.035 million |
| Research and development | $5.955 million | $5.747 million |
| Selling, general and administrative | $14.454 million | $11.046 million |
| Operating loss | $21.439 million | $16.813 million |
| Net loss | $21.758 million | $17.206 million |
| Basic and diluted loss per share | $0.80 | $0.65 |
| Operating cash used | $15.410 million | $14.394 million |
- Revenue remained small relative to costs; costs of revenue exceeded revenue by $1.030 million in the quarter.
- Cash and cash equivalents were $20.478 million and short-term investments were $89.610 million at March 31, 2016, totaling approximately $110.1 million, down from $126.7 million at December 31, 2015.
- Working capital was $100.9 million. Total liabilities were $13.2 million; the balance sheet lists no interest-bearing debt.
- Management expected available cash, cash equivalents and short-term investments to fund its current operating plan for at least 12 months, while cautioning that assumptions could prove wrong. No specific profitability or revenue guidance was given.
Material changes and developments
- Revenue rose by $0.131 million year over year, but the company completed only 24 AUGMENT treatments during the quarter and received biopsies for 21 additional patients. Revenue recognition was deferred until treatment delivery, typically 30–120 days or longer.
- Net loss increased $4.552 million year over year. SG&A increased 31%, primarily reflecting additional personnel, severance and international growth-related costs. R&D increased 4%.
- Operating cash use increased by about $1.0 million. There were no material financing proceeds in Q1 2016; Q1 2015 financing had included $124.1 million of net proceeds from a stock offering.
- OvaScience planned to expand AUGMENT activity in Canada and Japan, including two new Canadian clinic agreements, and to stop providing treatment in Turkey after ongoing patient cycles were completed. Management did not expect the Turkey exit to materially affect operating results.
- The company recorded a $0.391 million equity-method loss from its 50%-owned OvaXon joint venture and contributed approximately $0.8 million to the venture during the quarter.
Outlook, risks and unusual items
- Management anticipated modest near-term revenue growth, dependent on clinic enrollment and use of AUGMENT, and expected R&D and SG&A spending to increase as programs and international operations advance.
- The company expected continued losses and stated that substantial additional funding might be needed. It had no committed external source of capital; future equity or debt financing, collaborations or licensing could dilute shareholders, restrict operations or require concessions of rights.
- Key uncertainties include treatment efficacy and market acceptance, clinical and regulatory pathways, commercialization and reimbursement, competition, and the ability to obtain additional funding. AUGMENT was not available in the United States.
- A purported class action related to the January 2015 stock offering was consolidated in April 2016. The company said it believed the claims were without merit but could not estimate potential losses; an adverse resolution could materially affect financial position or results.
- A senior executive’s departure led to forfeiture of unvested options and a net $0.8 million reversal of stock-based compensation expense in Q1. The filing also reported $0.6 million of severance-related costs in SG&A.
- Management stated disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm that OvaScience, Inc.—rather than Tempest Therapeutics, Inc.—is the intended filing issuer.
- Review the clinical evidence, regulatory status and commercial uptake supporting AUGMENT, OvaPrime and OvaTure, including the ongoing AUGMENT study.
- Assess the cash runway against actual spending, planned expansion costs and the company’s stated dependence on future financing.
- Check subsequent developments in the consolidated securities litigation and any resulting exposure.
- Verify how deferred treatment revenue, pilot pricing and the cost structure affect reported revenue growth and treatment-level economics.